Source: Cure Today articles
The Food and Drug Administration granted an investigational new drug application and green lit the continued study of GC012F for the treatment of patients with relapsed/refractory myeloma.
Recent Content
- Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
- Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
- Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
- IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
- Combination induces durable responses in advanced multiple myeloma
- Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
- Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
- Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
- Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
- Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma